What is Centrose?
Centrose is at the forefront of oncology innovation, specializing in the development of Extracellular Drug Conjugates (EDCs). This novel class of ADCs targets the cell surfaceome, enabling precise cancer treatment by binding to multiple extracellular proteins without requiring internalization into the cell. The company's technology is engineered to enhance both the potency and safety profile of cancer therapeutics. Centrose's primary focus areas include drug-resistant non-Hodgkin lymphoma and various metastatic cancers, with a strategic objective to broaden its therapeutic target list and significantly improve patient outcomes.
How much funding has Centrose raised?
Centrose has raised a total of $4M across 3 funding rounds:
Debt
$500K
Debt
$2M
Private Equity
$1.4M
Debt (2010): $500K, investors not publicly disclosed
Debt (2013): $2M, investors not publicly disclosed
Private Equity (2015): $1.5M, investors not publicly disclosed
What's next for Centrose?
With substantial enterprise-level backing and a recent strategic investment, Centrose is well-positioned for accelerated growth and pipeline expansion. The company's focus on EDCs represents a significant advancement in targeted cancer therapy, potentially addressing unmet needs in difficult-to-treat cancers. Future endeavors will likely involve further clinical development, expanding the range of treatable cancers, and potentially forging strategic partnerships to bring their innovative therapies to a wider patient population. The sustained capital infusion indicates strong investor confidence in Centrose's technology and its potential to disrupt the oncology market.
See full Centrose company page
